Skip to main content
SpringerLink
Log in

Bone Disease in Patients with Cirrhosis

  • Chapter
  • First Online:
Complications of Cirrhosis

  • 1913 Accesses

Abstract

Osteoporosis resulting in a high fracture risk is a frequent complication in patients with liver disease, particularly in those with chronic cholestasis and end-stage cirrhosis. Osteomalacia is, however, exceptional and only presents when associated with persistent vitamin D deficiency in subjects with deep cholestasis. The pathogenesis of bone loss in these patients mainly results from low bone formation as a consequence of cholestasis or the harmful effects of alcohol or iron on osteoblasts. The management of bone disease in cirrhosis is addressed to reduce or avoid the risk factors for osteoporosis and fracture. Bisphosphonates associated with supplements of calcium and vitamin D are safe and effective for increasing bone mass in patients with chronic cholestasis and in cirrhotics after liver transplantation, though no clear achievements in decreasing the incidence of fractures have been described. Randomized studies assessing bisphosphonates in larger series of patients and the development of new drugs for osteoporosis may change future management. Clinicians must be aware of this frequent and detrimental complication in patients with cirrhosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Guañabens N, Pares A. Liver and bone. Arch Biochem Biophys. 2010;503:84–94.

    Article  PubMed  Google Scholar 

  2. Compston JE. Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease. Gut 1986;27:1073–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Report of a WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser. 1994;843:1–129.

    Google Scholar 

  4. Guañabens N, Parés A, Navasa M, Martínez de Osaba MJ, Hernández ME, Muñoz J, Rodés J. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. J Hepatol. 1994;21:24–8.

    Article  PubMed  Google Scholar 

  5. Springer JE, Cole DE, Rubin LA, Cauch-Dudek K, Harewood L, Evrovski J, Peltekova VD, Heathcote EJ. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000;118:145–51.

    Article  CAS  PubMed  Google Scholar 

  6. Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol. 2001;35:316–23.

    Article  CAS  PubMed  Google Scholar 

  7. Newton J, Francis R, Prince M, James O, Bassendine M, Rawlings D, Jones D. Osteoporosis in primary biliary cirrhosis revisited. Gut 2001;49:282–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Parés A, Guañabens N, Alvarez L, De Osaba MJ, Oriola J, Pons F, Caballería L, Monegal A, Salvador G, Jo J, Peris P, Rivera F, Ballesta AM, Rodés J. Collagen type I alpha 1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001;33:554–60.

    Article  PubMed  Google Scholar 

  9. Solerio E, Isaia G, Innarella R, Di Stefano M, Farina M, Borghesio E, Framarin L, Rizzetto M, Rosina F. Osteoporosis: still a typical complication of primary biliary cirrhosis? Dig Liver Dis. 2003;35:339–46.

    Article  CAS  PubMed  Google Scholar 

  10. Guañabens N, Parés A, Ros I, Caballería L, Pons F, Vidal S, Monegal A, Peris P, Rodés J. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol. 2005;42:573–7.

    Article  PubMed  Google Scholar 

  11. Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transplant. 2006;12:1390–402.

    Article  Google Scholar 

  12. Guanabens N, Cerda D, Monegal A, Pons F, Caballeria L, Peris P, Pares A. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010;138:2348–56.

    Article  PubMed  Google Scholar 

  13. Angulo P, Grandison GA, Fong DG, Keach JC, Lindor KD, Bjornsson E, Koch A. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011;140:180–8.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Bonkovsky HL, Hawkins M, Steinberg K, Hersh T, Galambos JT, Henderson JM, Millikan WJ, Galloway JR. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990;12:273–80.

    Article  CAS  PubMed  Google Scholar 

  15. Diamond T, Stiel D, Lunzer M, Wilkinson M, Roche J, Posen S. Osteoporosis and skeletal fractures in chronic liver disease. Gut 1990;31:82–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Chen CC, Wang SS, Jeng FS, Lee SD. Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol. 1996;11:417–21.

    Article  CAS  PubMed  Google Scholar 

  17. Monegal A, Navasa M, Guañabens N, Peris P, Pons F, Martinez de Osaba MJ, Rimola A, Rodés J, Muñoz-Gómez J. Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int. 1997;60:148–54.

    Article  CAS  PubMed  Google Scholar 

  18. Ninkovic M, Skingle SJ, Bearcroft PW, Bishop N, Alexander GJ, Compston JE. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol. 2000;12:931–5.

    Article  CAS  PubMed  Google Scholar 

  19. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int. 2001;69:321–6.

    Article  CAS  PubMed  Google Scholar 

  20. Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transplant. 2003;9:1166–73.

    Article  Google Scholar 

  21. Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transplant. 2004;10:648–53.

    Article  Google Scholar 

  22. González-Calvin JL, Mundi JL, Casado-Caballero FJ, Abadia AC, Martin-Ibañez JJ. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. J Clin Endocrinol Metab. 2009;94:4844–50.

    Article  PubMed  Google Scholar 

  23. Monegal A, Navasa M, Peris P, Colmenero J, Cuervo A, Muxí A, Gifre L, Guañabens N. Bone disease in patients awaiting liver transplantation. Has the situation improved in the last two decades? Calcif Tissue Int. 2013;93:571–6.

    Article  CAS  PubMed  Google Scholar 

  24. Sinigaglia L, Fargion S, Fracanzani AL, Binelli L, Battafarano N, Varenna M, Piperno A, Fiorelli G. Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. J Rheumatol. 1997;24:1809–13.

    CAS  PubMed  Google Scholar 

  25. Guggenbuhl P, Deugnier Y, Boisdet JF, Rolland Y, Perdriger A, Pawlotsky Y, Chales G. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int. 2005;16:1809–14.

    Article  CAS  PubMed  Google Scholar 

  26. Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S, Sinigaglia L. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int. 2009;20:549–55.

    Article  CAS  PubMed  Google Scholar 

  27. Olsson R, Johansson C, Lindstedt G, Mellstrom D. Risk factors for bone loss in chronic active hepatitis and primary biliary cirrhosis. Scand J Gastroenterol. 1994; 29: 753–6.

    Article  CAS  PubMed  Google Scholar 

  28. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, Ordi J, Rimola A, Rodes J, Munoz-Gomez J. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int. 2001;12:484–92.

    Article  CAS  PubMed  Google Scholar 

  29. Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, Otto G, Lange R, Theilmann L, Zimmerman R, Pritsch M, Ziegler R. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 2001;357:342–7.

    Article  CAS  PubMed  Google Scholar 

  30. Navasa M, Monegal A, Guanabens N, Peris P, Rimola A, Munoz-Gomez J, Visa J, Rodes J. Bone fractures in liver transplant patients. Br J Rheumatol. 1994;33:52–5.

    Article  CAS  PubMed  Google Scholar 

  31. Compston JE. Osteoporosis after liver transplantation. Liver Transplant. 2003;9:321–30.

    Article  Google Scholar 

  32. Stellon AJ, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology 1987;7:137–42.

    Article  CAS  PubMed  Google Scholar 

  33. Guanabens N, Pares A, Marinoso L, Brancos MA, Piera C, Serrano S, Rivera F, Rodes J. Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol. 1990;85:1356–62.

    CAS  PubMed  Google Scholar 

  34. Guanabens N, Pares A, Alvarez L, Martinez de Osaba MJ, Monegal A, Peris P, Ballesta AM, Rodes J. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res. 1998;13:731–8.

    Article  CAS  PubMed  Google Scholar 

  35. Ruiz-Gaspa S, Guanabens N, Enjuanes A, Peris P, Martinez-Ferrer A, de Osaba MJ, Gonzalez B, Alvarez L, Monegal A, Combalia A, Pares A. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest. 2010;40:25–34.

    Article  CAS  PubMed  Google Scholar 

  36. Ruiz-Gaspà S, Martinez-Ferrer A, Guañabens N, Dubreuil M, Peris P, Enjuanes A, Martinez de Osaba MJ, Alvarez L, Monegal A, Combalia A, Parés A. Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology 2011;54:2104–13.

    Article  PubMed  Google Scholar 

  37. Dubreuil M, Ruiz-Gaspà S, Guañabens N, Peris P, Alvarez L, Monegal A, Combalia A, Parés A. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. Liver Int. 2013;33:1029–38.

    Article  CAS  PubMed  Google Scholar 

  38. Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998;28:695–9.

    Article  CAS  PubMed  Google Scholar 

  39. Cemborain A, Castilla-Cortazar I, Garcia M, Quiroga J, Muguerza B, Picardi A, Santidrian S, Prieto J. Osteopenia in rats with liver cirrhosis: beneficial effects of IGF-I treatment. J Hepatol. 1998;28:122–31.

    Article  CAS  PubMed  Google Scholar 

  40. Nakchbandi IA, van der Merwe SW. Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:660–70.

    Article  PubMed  Google Scholar 

  41. Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, Casado-Caballero F, Ruiz-Escolano E, Olivares EG. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab. 2004;89:4325–4330.

    Article  CAS  PubMed  Google Scholar 

  42. Cuthbert JA, Pak CY, Zerwekh JE, Glass KD, Combes B. Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 1984;4:1–8.

    Article  CAS  PubMed  Google Scholar 

  43. Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 1993;14:819–27.

    Article  CAS  PubMed  Google Scholar 

  44. McCaughan GW, Feller RB. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig Dis. 1994;12:223–31.

    Article  CAS  PubMed  Google Scholar 

  45. Diamond T, Stiel D, Lunzer M, Wilkinson M, Posen S. Ethanol reduces bone formation and may cause osteoporosis. Am J Med. 1989; 86:282–8.

    Article  CAS  PubMed  Google Scholar 

  46. Peris P, Pares A, Guanabens N, Pons F, Martinez de Osaba MJ, Caballeria J, Rodes J, Munoz-Gomez J. Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics. Alcohol Alcohol. 1992;27:619–25.

    CAS  PubMed  Google Scholar 

  47. Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med. 1989;110:430–6.

    Article  CAS  PubMed  Google Scholar 

  48. Pares A, Guanabens N, Rodes J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2005;17:311–5.

    Article  CAS  PubMed  Google Scholar 

  49. Pares A, Guanabens N. Treatment of bone disorders in liver disease. J Hepatol. 2006;45:445–53.

    Article  CAS  PubMed  Google Scholar 

  50. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941–66.

    Article  PubMed  Google Scholar 

  51. Guañabens N, Monegal A, Muxi A, Martinez-Ferrer A, Reyes R, Caballería J, Del Río L, Peris P, Pons F, Parés A. Patients with cirrhosis and ascites have false values of bone density: implications for the diagnosis of osteoporosis. Osteoporos Int. 2012;23:1481–7.

    Article  PubMed  Google Scholar 

  52. Guanabens N, Pares A, Monegal A, Peris P, Pons F, Alvarez L, de Osaba MJ, Roca M, Torra M, Rodes J. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997;113:219–24.

    Article  CAS  PubMed  Google Scholar 

  53. Wolfhagen FH, van Buuren HR, den Ouden JW, Hop WC, van Leeuwen JP, Schalm SW, Pols HA. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol. 1997;26:325–30.

    Article  CAS  PubMed  Google Scholar 

  54. Lindor KD, Jorgensen RA, Tiegs RD, Khosla S, Dickson ER. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol. 2000;33:878–82.

    Article  CAS  PubMed  Google Scholar 

  55. Guanabens N, Pares A, Ros I, Alvarez L, Pons F, Caballeria L, Monegal A, Martinez de Osaba MJ, Roca M, Peris P, Rodes J. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98:2268–74.

    Article  CAS  PubMed  Google Scholar 

  56. Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, Lindor KD. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005;42:762–71.

    Article  CAS  PubMed  Google Scholar 

  57. Guanabens N, Vazquez I, Alvarez L, Pons F, Caballeria L, Cerda D, Peris P, Monegal A, Pares A. Alendronate 70 mg once-weekly is more effective and has a better tolerability than alendronate 10 mg daily in the treatment of osteopenia aassociated with primary biliary cirrhosis. JBMR. 2005;20:S279.

    Google Scholar 

  58. Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A, Margreiter R, Vogel W. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transplant. 2005;11:960–6.

    Article  Google Scholar 

  59. Atamaz F, Hepguler S, Akyildiz M, Karasu Z, Kilic M. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporos Int. 2006;17:942–9.

    Article  CAS  PubMed  Google Scholar 

  60. Guañabens N, Monegal A, Cerdá D, Muxí Á, Gifre L, Peris P, Parés A. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology 2013;58:2070–8.

    Article  PubMed  Google Scholar 

  61. Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc. 2002;77:1031–43.

    Article  PubMed  Google Scholar 

  62. Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol. 2002;37:93–100.

    Article  CAS  PubMed  Google Scholar 

  63. Dodidou P, Bruckner T, Hosch S, Haass M, Klar E, Sauer P, Ziegler R, Leidig-Bruckner G. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int. 2003;14:82–9.

    Article  CAS  PubMed  Google Scholar 

  64. Monegal A, Guanabens N, Suarez MJ, Suarez F, Clemente G, Garcia-Gonzalez M, De la MM, Serrano T, Casafont F, Tome S, Barrios C, Navasa M. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial. Transpl Int. 2009;22:198–206.

    Article  CAS  PubMed  Google Scholar 

  65. Crawford BA, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaughan GW. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144:239–48.

    Article  CAS  PubMed  Google Scholar 

  66. Misof BM, Bodingbauer M, Roschger P, Wekerle T, Pakrah B, Haas M, Kainz A, Oberbauer R, Muhlbacher F, Klaushofer K. Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation. Calcif Tissue Int. 2008;83:167–75.

    Article  CAS  PubMed  Google Scholar 

  67. Olsson R, Mattsson LA, Obrant K, Mellström D. Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver 1999;19:188–92.

    Article  CAS  PubMed  Google Scholar 

  68. Pereira SP, OʼDonohue J, Moniz C, Phillips MG, Abraha H, Buxton-Thomas M, Williams R. Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. Aliment Pharmacol Ther. 2004;19:563–70.

    Article  CAS  PubMed  Google Scholar 

  69. Ormarsdóttir S, Mallmin H, Naessén T, Petrén-Mallmin M, Broomé U, Hultcrantz R, Lööf L. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med. 2004;256:63–9.

    Article  PubMed  Google Scholar 

  70. Isoniemi H, Appelberg J, Nilsson CG, Mäkelä P, Risteli J, Höckerstedt K. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol. 2001;34(2):299–305.

    Article  CAS  PubMed  Google Scholar 

  71. Diamond T, Stiel D, Posen S. Effects of testosterone and venesection on spinal and peripheral bone mineral in six hypogonadal men with hemochromatosis. J Bone Miner Res. 1991;6:39–43.

    Article  CAS  PubMed  Google Scholar 

  72. Dresner-Pollak R, Gabet Y, Steimatzky A, Hamdani G, Bab I, Ackerman Z, Weinreb M. Human parathyroid hormone 1–34 prevents bone loss in experimental biliary cirrhosis in rats. Gastroenterology 2008;134:259–67.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Unit, Hospital Clínic, CIBERhed, IDIBAPS, University of Barcelona, C/Villarroel 170, 08036, Barcelona, Spain

    Albert Parés MD

  2. Metabolic Bone Diseases Unit, Department of Rheumatology, Hospital Clínic, CIBERhed, IDIBAPS, University of Barcelona, Barcelona, Spain

    Núria Guañabens MD

Authors
  1. Albert Parés MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Núria Guañabens MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert Parés MD .

Editor information

Editors and Affiliations

  1. Department of Transplant, Mayo Clinic, Jacksonville, Florida, USA

    Andrew P. Keaveny

  2. Institut de Malalties Digestives i Metaboliques, University of Barcelona, Barcelona, Spain

    Andrés Cárdenas

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Parés, A., Guañabens, N. (2015). Bone Disease in Patients with Cirrhosis. In: Keaveny, A., Cárdenas, A. (eds) Complications of Cirrhosis. Springer, Cham. https://doi.org/10.1007/978-3-319-13614-1_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-13614-1_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-13613-4

  • Online ISBN: 978-3-319-13614-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation